Raymond James on Viking Therapeutic (VKTX): 'Our analysis of this dataset suggests semaglutide does not have a lean body mass preservation advantage'
Tweet Send to a Friend
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $118.00 price target on Viking Therapeutic (NASDAQ: VKTX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
